InMed Pharmaceuticals Inc. (INM): Revenue
$4.94M
Year ended 2025-06-30
+65.5%
3-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $4.94M | +7.5% | 2025-09-23, From 2024-07-01 |
| 2024-06-30 | $4.60M | +11.2% | 2025-09-23, From 2023-07-01 |
| 2023-06-30 | $4.14M | +279.6% | 2024-09-30, From 2022-07-01 |
| 2022-06-30 | $1.09M | n/a | 2023-09-29, From 2021-07-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | 2025-06-30 | $4.94M | +7.5% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $5.0K | -50.0% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.40M | n/a |
| Procyon Corp (PCYN) | 2024-06-30 | $4.98M | +6.4% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $40.0K | -51.8% |
| BullFrog AI Holdings, Inc. (BFRG) | 2025-12-31 | $116.7K | n/a |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $536.4K | +19.3% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $601.0K | +5.4% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $705.9K | +52.0% |
Compare INM, TCRT, ATXI, PCYN side by side · Screen every company in Pharmaceutical Preparations ↗